Utility of anti-ccp in monitoring activity of rheumatoid arthritis
Keywords:
Rheumatoid arthritis, Antibody anti cyclic citrullinated peptide, DAS 28Abstract
and are the most specific for the diagnosis of this disease. However, the results in terms of their usefulness in monitoring treatment have been mixed. Objective: Determining the usefulness of anti-CCP in monitoring the activity of rheumatoid arthritis and the prev- alence of these patients depending on the type of therapy at which they were exposed. Materials and methods: Study of diagnostic test evaluation, conducted to patients in outpatient unit of the Atlan- tic Medical Research services provider institution, in Barranquilla, Colombia. Intentional non-probability sampling, which included 39 patients who met the criteria for classification of rheumatoid arthritis to which we evaluated the sensitivity, specificity, and predictive values of anti-CCP for the monitoring of disease activity using as gold standard the DAS 28. Results: The anti-CCP had a sensitivity of 57%, specificity 25%, positive predictive value 86% and negative predic- tive value of 6%, when establishing activity and remission. Conclusion: Anti-CCP antibodies are a useful diagnostic test to predict disease activity, but it has limitations when setting the states of remission.
Downloads
References
2.Caballero UC. Clinimetría en Reumatología. En: Molina LJ, Molina RJ, editores. Reuma- tología fundamentos de medicina. Medellín: Cib; 2012.
3.Pincus T. Are patient questionnaire scores as “scientific” as laboratory tests for rheumato- logy clinical care. Bull NYU Hosp Jt Dis. 2010; 68(2):130-9.
4.Pincus T, Yazici Y, Bergman M. Patient Ques- tionnaires in Rheumatoid Arthritis: Advanta- ges and Limitations as a Quantitative Stan- dardized Scientific Medical. Rheum Dis Clin North Am. 2009; 68(2):8-17.
5.Mikuls, T, Dell JR, Stoner JA, Parrish LA, Arend WP, Norris JM. Association of Rheumatoid Arthritis Treatment Response and Disease Duration With Declines in Serum Levels of IgM Rheumatoid Factor and Anti-Cyclic Citru- llinated Peptide Antibody. Arthritis Rheum. 2004; 50:3776-82.
6.- ce of anti-citrullinated protein antibodies (ACPA) and rheumatoid factor on patients with rheumatoid arthritis (RA) does not in- terfere with the chance of clinical remission in a follow-up of 3 years. Rheumatol Int. 2011; 32(12):3807-12.
7.Miriovsky B, Michaud K, Thiele GM, O’Dell JR, Cannon GW, Kerr G. Anti-CCP antibo- dy and rheumatoid factor concentrations predict greater disease activity in men with rheumatoid arthritis. Ann Rheum Dis. 2010; 69(7):1292-7.
8.Verschueren P, Esselens G, Westhovens R. Predictors of remission, normalized physical function, and changes in the working situa- tion during follow-up of patients with early rheumatoid arthritis: an observational study. Scand J Rheumatol. 2009; 38(3):166-72.
9.Serdaroflu M, Çakırbay H, Değer H, Cengiz S, Kul S. Theassociation of anti-CCP antibodies with disease activity in rheumatoid arthritis. Rheumatol Int. 2008; 28:965-70.
10.Gossec L, Dougados M, Goupille P, Cantagrel A, Sibila J, Meyer O. Prognostic factors for re- mission in early rheumatoid arthritis: a mul- tiparameter prospective study. Ann Rheum Dis. 2004; 63(6):1-6.
11.Boire G, Cossette P, de Brum-Fernandes A, Liang P, Niyonsenga T, Zhou Z, et al. Anti- Saantibodies and antibodies against cyclic ci- trullinated peptide are not equivalent as pre- dictors of severe outcomes in patients with recent-onset polyarthritis. Arthritis Res Ther. 2004; 7(3):1-12.
12.Karifi mar M, Salesi M, Farajzdegan Z. The association of anti-CCP1 antibodies with dis- ease activity score 28 (DAS-28) in rheuma- toid arthritis. [serie en Internet]. Ady Biomed Res. 2012 [citado oct 1 2012]; 1: 30-1. Dis- ponible en: http://www.ncloi.nlm.nih.gov/ pmc/articles/PMC35070301
Downloads
Published
Issue
Section
License
-
Reconocimiento — Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios<. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.
-
NoComercial — No puede utilizar el material para una finalidad comercial.
-
CompartirIgual — Si remezcla, transforma o crea a partir del material, deberá difundir sus contribuciones bajo la misma licencia que el original.
- No hay restricciones adicionales — No puede aplicar términos legales o medidas tecnológicas que legalmente restrinjan realizar aquello que la licencia permite.
